New hepatitis b cocktail shows promise in Mid-Stage trial
NCT ID NCT04856085
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 28 times
Summary
This study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely clear the hepatitis B virus from the blood. 244 adults with chronic hepatitis B who were already on antiviral therapy took part. The main goals were to check for side effects and see if the virus's surface antigen (HBsAg) became undetectable, which is a key step toward controlling the infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site
Seoul, 03080, South Korea
-
Investigative Site
Seoul, 05505, South Korea
-
Investigative Site
Yangsan, 50612, South Korea
-
Investigative Site
Chiayi City, 60041, Taiwan
-
Investigative Site
Kaohsiung City, 80756, Taiwan
-
Investigative Site
Kaohsiung City, 83301, Taiwan
-
Investigative Site
Taichung, 40705, Taiwan
-
Investigative Site
Taipei, 100, Taiwan
-
Investigative Site
Taoyuan City, 33305, Taiwan
-
Investigative Site
Kyiv, 01135, Ukraine
-
Investigative Site
Birmingham, B15 2TH, United Kingdom
-
Investigative Site
London, E11FR, United Kingdom
-
Investigative Site
London, SE5 9RS, United Kingdom
-
Investigative Site
Manchester, M8 5RB, United Kingdom
-
Investigative Site
San Francisco, California, 94143, United States
-
Investigative Site
Miami, Florida, 33136, United States
-
Investigative Site
Orlando, Florida, 32803, United States
-
Investigative Site
Baltimore, Maryland, 21218, United States
-
Investigative Site
Hillsborough, New Jersey, 08844, United States
-
Investigative Site
Toronto, 2C4, Canada
-
Investigative Site
Toronto, 3M1, Canada
-
Investigative Site
Vancouver, 2C7, Canada
-
Investigative Site
Frankfurt, 60590, Germany
-
Investigative Site
Hanover, 30625, Germany
-
Investigative Site
Mannheim, 68167, Germany
-
Investigative Site
Hong Kong, Shatin, Hong Kong
-
Investigative Site
Hong Kong, Tai Po District, Hong Kong
-
Investigative Site
Hong Kong, Hong Kong
-
Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Investigative Site
Chisinau, MD 2025, Moldova
-
Investigative Site
Auckland, 1010, New Zealand
-
Investigative Site
Auckland, 2025, New Zealand
-
Investigative Site
Hamilton, 3204, New Zealand
-
Investigative Site
Tauranga, 3110, New Zealand
-
Investigative Site
Wellington, 6021, New Zealand
-
Investigative Site
Bucharest, 021105, Romania
-
Investigative Site
Busan, 49421, South Korea
Conditions
Explore the condition pages connected to this study.